Short Interest in PDS Biotechnology Corporation (NASDAQ:PDSB) Rises By 61.8%

PDS Biotechnology Corporation (NASDAQ:PDSB) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 2,172,765 shares, a growth of 61.8% from the December 31st total of 1,343,277 shares. Currently, 4.9% of the company’s shares are short sold. Based on an average daily volume of 898,913 shares, the short-interest ratio is presently 2.4 days. Based on an average daily volume of 898,913 shares, the short-interest ratio is presently 2.4 days. Currently, 4.9% of the company’s shares are short sold.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PDSB. Inspirion Wealth Advisors LLC boosted its stake in shares of PDS Biotechnology by 338.5% during the third quarter. Inspirion Wealth Advisors LLC now owns 344,394 shares of the company’s stock valued at $348,000 after purchasing an additional 265,862 shares in the last quarter. Squarepoint Ops LLC raised its holdings in PDS Biotechnology by 116.1% in the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after buying an additional 156,662 shares during the last quarter. Susquehanna International Group LLP boosted its position in PDS Biotechnology by 603.7% during the 3rd quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after buying an additional 80,937 shares during the period. Jane Street Group LLC bought a new stake in PDS Biotechnology during the 2nd quarter worth approximately $92,000. Finally, Marshall Wace LLP acquired a new position in PDS Biotechnology in the 2nd quarter valued at approximately $91,000. Institutional investors own 26.84% of the company’s stock.

Analyst Ratings Changes

PDSB has been the topic of several recent analyst reports. B. Riley dropped their price target on PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, November 25th. HC Wainwright raised their target price on PDS Biotechnology from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Trading Down 4.5%

Shares of NASDAQ:PDSB traded down $0.04 during midday trading on Friday, hitting $0.83. The company had a trading volume of 391,212 shares, compared to its average volume of 863,702. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. PDS Biotechnology has a 12 month low of $0.70 and a 12 month high of $2.20. The stock has a market cap of $40.79 million, a price-to-earnings ratio of -1.02 and a beta of 1.12. The firm has a fifty day simple moving average of $0.89 and a 200 day simple moving average of $1.01.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. On average, analysts predict that PDS Biotechnology will post -1.2 EPS for the current year.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.